Regular
NAV (06-Sep-24)
Returns (Since Inception)
Fund Size
₹344 Cr
Expense Ratio
2.39%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+35.52%
— (Cat Avg.)
Equity | ₹338.19 Cr | 98.24% |
Others | ₹6.05 Cr | 1.76% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹52.27 Cr | 15.18% |
Cipla Ltd | Equity | ₹28.57 Cr | 8.30% |
Zydus Lifesciences Ltd | Equity | ₹22.33 Cr | 6.49% |
Divi's Laboratories Ltd | Equity | ₹17.72 Cr | 5.15% |
Dr Reddy's Laboratories Ltd | Equity | ₹16.88 Cr | 4.90% |
Torrent Pharmaceuticals Ltd | Equity | ₹16.49 Cr | 4.79% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹16.42 Cr | 4.77% |
Aurobindo Pharma Ltd | Equity | ₹13.91 Cr | 4.04% |
Marksans Pharma Ltd | Equity | ₹13.4 Cr | 3.89% |
Innova Captab Ltd | Equity | ₹11.27 Cr | 3.27% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.02 Cr | 3.20% |
Ajanta Pharma Ltd | Equity | ₹10.61 Cr | 3.08% |
Alkem Laboratories Ltd | Equity | ₹10.09 Cr | 2.93% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹9.77 Cr | 2.84% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8.93 Cr | 2.59% |
Laurus Labs Ltd | Equity | ₹7.56 Cr | 2.20% |
Metropolis Healthcare Ltd | Equity | ₹7.25 Cr | 2.11% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹7.1 Cr | 2.06% |
Fortis Healthcare Ltd | Equity | ₹6.78 Cr | 1.97% |
Alembic Pharmaceuticals Ltd | Equity | ₹6.61 Cr | 1.92% |
Triparty Repo | Cash - Repurchase Agreement | ₹6.6 Cr | 1.92% |
Jubilant Pharmova Ltd | Equity | ₹6.57 Cr | 1.91% |
Biocon Ltd | Equity | ₹6.49 Cr | 1.88% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹6.44 Cr | 1.87% |
Emcure Pharmaceuticals Ltd | Equity | ₹6.41 Cr | 1.86% |
GPT Healthcare Ltd | Equity | ₹6.15 Cr | 1.79% |
Ami Organics Ltd | Equity | ₹6.02 Cr | 1.75% |
Narayana Hrudayalaya Ltd | Equity | ₹5.15 Cr | 1.50% |
Net Current Assets/(Liabilities) | Cash | ₹-0.55 Cr | 0.16% |
Large Cap Stocks
40.92%
Mid Cap Stocks
31.92%
Small Cap Stocks
21.75%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹332.17 Cr | 96.49% |
Basic Materials | ₹6.02 Cr | 1.75% |
Standard Deviation
This fund
--
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since December 2023
Since December 2023
Since December 2023
Since March 2024
ISIN | INF174KA1PW4 | Expense Ratio | 2.39% | Exit Load | 1.00% | Fund Size | ₹344 Cr | Age | 11 Dec 2023 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹4,96,460 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk